Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cobicistat

FDA-approved product (tablet, oral), marketed as Cobicistat, Tybost.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Cobicistat
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • HIV-1 infection
  • Infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other therapeutic products
FDA pharmacologic class
Cytochrome P450 3A Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA54.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli46.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis54.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Cobicistat in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cobicistat with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Interaction With HIV Antiretroviral Agents

    NCT02556268 · start 2016-02-23

    Registered record
    Registry ID
    NCT02556268
    Conditions
    HIV-DDI
    Interventions
    Riociguat (Adempas, BAY 63-2521); ATRIPLA; COMPLERA; STRIBILD; TRIUMEQ; Antiretroviral protease inhibitor
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-02-23
    Completion
    2016-12-07
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-DDI
    InterventionRiociguat (Adempas, BAY 63-2521); ATRIPLA; COMPLERA; STRIBILD +2 more
    PhasePhase 1
    Registry statusCompleted

  • Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women

    NCT02652624 · start 2016-02-19

    Registered record
    Registry ID
    NCT02652624
    Conditions
    HIV-1 Infection
    Interventions
    E/C/F/TAF; E/C/F/TDF; ATV; RTV; FTC/TDF; B/F/TAF
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-02-19
    Completion
    2018-11-26
    Enrolment
    472

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    InterventionE/C/F/TAF; E/C/F/TDF; ATV; RTV +2 more
    PhasePhase 3
    Registry statusCompleted

  • Elvitegravir (EVG) Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected Individuals

    NCT02251236 · start 2016-01

    Registered record
    Registry ID
    NCT02251236
    Conditions
    HIV
    Interventions
    Stribild; Genvoya
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2016-01
    Completion
    2017-01-18
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionStribild; Genvoya
    PhaseNot applicable
    Registry statusCompleted

  • Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I

    NCT02616029 · start 2015-12-17

    Registered record
    Registry ID
    NCT02616029
    Conditions
    HIV-1 Infection
    Interventions
    E/C/F/TAF
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-12-17
    Completion
    2019-07-11
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    InterventionE/C/F/TAF
    PhasePhase 3
    Registry statusCompleted

  • Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults

    NCT02603107 · start 2015-11-20

    Registered record
    Registry ID
    NCT02603107
    Conditions
    HIV-1 Infection
    Interventions
    RTV; ATV; DRV; COBI; ATV/co; DRV/co; FTC/TDF; ABC/3TC; B/F/TAF
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-11-20
    Completion
    2019-12-23
    Enrolment
    578

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    InterventionRTV; ATV; DRV; COBI +5 more
    PhasePhase 3
    Registry statusCompleted

  • Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults

    NCT02605954 · start 2015-11-18

    Registered record
    Registry ID
    NCT02605954
    Conditions
    HIV-1 Infection
    Interventions
    E/C/F/TAF; ABC/3TC; Third Antiretroviral Agent
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-11-18
    Completion
    2018-01-24
    Enrolment
    275

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    InterventionE/C/F/TAF; ABC/3TC; Third Antiretroviral Agent
    PhasePhase 3
    Registry statusCompleted

  • A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/Cobicistat

    NCT02565888 · start 2015-11

    Registered record
    Registry ID
    NCT02565888
    Conditions
    Hepatitis C; HIV
    Interventions
    Daclatasvir; Atazanavir; Ritonavir; Cobicistat
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-11
    Completion
    2016-01
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C; HIV
    InterventionDaclatasvir; Atazanavir; Ritonavir; Cobicistat
    PhasePhase 1
    Registry statusCompleted

  • Effect of Cobicistat Versus Ritonavir Boosting on the Brain Permeation of Darunavir in HIV-infected Individuals

    NCT02503462 · start 2015-07

    Registered record
    Registry ID
    NCT02503462
    Conditions
    AIDS-related Dementia Complex
    Interventions
    Darunavir; ritonavir; cobicistat
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2015-07
    Completion
    2017-01
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAIDS-related Dementia Complex
    InterventionDarunavir; ritonavir; cobicistat
    PhasePhase 4
    Registry statusTerminated

  • Renal Integrase Study

    NCT02351908 · start 2015-03

    Registered record
    Registry ID
    NCT02351908
    Conditions
    HIV
    Interventions
    Stribild® (Tenofovir Disoproxil Fumarate, Elvitegravir, Cobicistat); Isentress® (Raltegravir 400 mg)1 tablet twice a day + Truvada® (FTC & Tenofovir) 1 tablet; Tivicay® (Dolutegravir 50 mg) 1 tablet once a day + Truvada® (FTC & Tenofovir)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-03
    Completion
    2017-04
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionStribild® (Tenofovir Disoproxil Fumarate, Elvitegravir, Cobicistat); Isentress® (Raltegravir 400 mg)1 tablet twice a day + Truvada® (FTC & Tenofovir) 1 tablet; Tivicay® (Dolutegravir 50 mg) 1 tablet once a day + Truvada® (FTC & Tenofovir)
    PhasePhase 4
    Registry statusCompleted

  • Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy

    NCT02302547 · start 2014-12

    Registered record
    Registry ID
    NCT02302547
    Conditions
    HIV
    Interventions
    triple therapy; dual therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-12
    Completion
    2018-09-21
    Enrolment
    224

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    Interventiontriple therapy; dual therapy
    PhasePhase 3
    Registry statusCompleted

  • SSAT061: PK of DTG and EVT/COBI in Healthy Volunteers

    NCT02219217 · start 2014-10

    Registered record
    Registry ID
    NCT02219217
    Conditions
    HIV
    Interventions
    Dolutegravir, Elvitegravir and Cobicistat
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-10
    Completion
    2015-01
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionDolutegravir, Elvitegravir and Cobicistat
    PhasePhase 1
    Registry statusCompleted

  • Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy and Switch to an Elvitegravir-based Regimen

    NCT01929759 · start 2014-01

    Registered record
    Registry ID
    NCT01929759
    Conditions
    HIV Disease
    Interventions
    Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2014-01
    Completion
    2015-10
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Disease
    InterventionStribild (elvitegravir, cobicistat, emtricitabine and tenofovir)
    PhaseNot applicable
    Registry statusCompleted

  • Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment

    NCT01818596 · start 2013-03-27

    Registered record
    Registry ID
    NCT01818596
    Conditions
    HIV; HIV Infections
    Interventions
    E/C/F/TAF
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-03-27
    Completion
    2018-07-18
    Enrolment
    252

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV; HIV Infections
    InterventionE/C/F/TAF
    PhasePhase 3
    Registry statusCompleted

  • Pharmacokinetics, Safety, and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in Adolescents

    NCT01721109 · start 2012-12-06

    Registered record
    Registry ID
    NCT01721109
    Conditions
    Acquired Immunodeficiency Syndrome; HIV Infections
    Interventions
    EVG/COBI/FTC/TDF
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2012-12-06
    Completion
    2018-01-29
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcquired Immunodeficiency Syndrome; HIV Infections
    InterventionEVG/COBI/FTC/TDF
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women

    NCT01705574 · start 2012-10-24

    Registered record
    Registry ID
    NCT01705574
    Conditions
    Acquired Immunodeficiency Syndrome; HIV Infections
    Interventions
    E/C/F/TDF; ATV; RTV; FTC/TDF; E/C/F/TDF Placebo; ATV Placebo; RTV Placebo; FTC/TDF Placebo; E/C/F/TAF
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-10-24
    Completion
    2018-09-06
    Enrolment
    583

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcquired Immunodeficiency Syndrome; HIV Infections
    InterventionE/C/F/TDF; ATV; RTV; FTC/TDF +5 more
    PhasePhase 3
    Registry statusCompleted